<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J. Korean Med. Sci</journal-id><journal-id journal-id-type="publisher-id">JKMS</journal-id><journal-title-group><journal-title>Journal of Korean Medical Science</journal-title></journal-title-group><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>The Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26339182</article-id><article-id pub-id-type="pmc">4553689</article-id><article-id pub-id-type="doi">10.3346/jkms.2015.30.9.1373</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Erratum: A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin&#x000ae; in Patients with Type 1 Gaucher Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Jin-Ho</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Beom Hee</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ko</surname><given-names>Jung Min</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sohn</surname><given-names>Young Bae</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jin-Sung</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Gu-Hwan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Heo</surname><given-names>Sun Hee</given-names></name></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>June-Young</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Yoo-Mi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Ja-Hye</given-names></name></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yoo</surname><given-names>Han-Wook</given-names></name></contrib></contrib-group><author-notes><corresp>
Address for Correspondence: Han-Wook Yoo, MD. Department of Pediatrics, Asan Medical Center Children's Hospital, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea. Tel.: +82.2 3010 3374, Fax: +82.2 473 3725, <email>hwyoo@amc.seoul.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>13</day><month>8</month><year>2015</year></pub-date><volume>30</volume><issue>9</issue><fpage>1373</fpage><lpage>1373</lpage><permissions><copyright-statement>&#x000a9; 2015 The Korean Academy of Medical Sciences.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><related-article related-article-type="corrected-article" id="d35e132" vol="30" page="378" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="25829804" ext-link-type="pubmed"><article-title>A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin&#x000ae; in Patients with Type 1 Gaucher Disease</article-title></related-article></article-meta></front><body><p>To the Editor:</p><p>The authors want to clarify the definition of "biosimilar" based on "Regulatory expectations and risk assessment for biotherapeutic products. World Health Organization 2014. available from <ext-link ext-link-type="uri" xlink:href="http://www.who.int/biologicals/WHO_Risk_Assessment_for_Biotherapeutics_1st_PC_24_Jan_2014.pdf">http://www.who.int/biologicals/WHO_Risk_Assessment_for_Biotherapeutics_1st_PC_24_Jan_2014.pdf</ext-link>"</p><p>In this article (J Korean Med Sci 2015;30:378-384), as Abcertin&#x000ae; does not meet the exact definition of biosimilar, the authors would like to delete the phrases "a biosimilar of imiglucerase" in Page 379 and "a new biosimilar to imiglucerase" in Page 382.</p><p>Thank you.</p><p>Sincerely yours,</p><p>Yoo HW</p></body></article>